Johnson & Johnson Seeks FDA Clearance for Booster Doses

Johnson & Johnson on Tuesday petitioned the Food and Drug Administration to approve a booster shot of its single-dose COVID-19 vaccine for people 18 years and older.

J&J’s application indicatded that a late-stage study shows that a booster dose given 56 days after the primary dose provides up to 94% protection against developing an active COVID-19 infection and provides 100% protection against developing severe COVID disease 14 days after the booster shot is received 

The FDA has scheduled an October 15advisory committee meeting to discuss the authorization request.

The FDA has already authorized a booster dose of Pfizer’s for those that are 65-years of age and older, people that are at high risk of severe COVID disease and anyone who is regularly exposed to the virus.


© Fourth Estate® — All Rights Reserved.
This material may not be published, broadcast, rewritten or redistributed.